Amarin Corp Plc (AMRN)

[ralphey]

AMARIN (AMRN): A Case Study in Strategic Failure — Shareholders Must Pursue Legal Action for Fiduciary Breach

The Blunder That Nuked Billions in Value:

Amarin’s REDUCE-IT trial, while scientifically robust, was a commercial failure in disguise — because it excluded statin-intolerant patients, a population that makes up 10–20% of the dyslipidemia market.

Any competent medical student — let alone a biotech CEO — should have known better. This wasn’t a minor oversight.
It was a blatant act of strategic malpractice.

The consequence? VASCEPA was boxed out of the very niche it could have dominated. Esperion capitalized on the error, capturing the statin-intolerant market with Nexletol, backed by CLEAR Outcomes.

The Numbers Don’t Lie — They Scream:

2007: ~$1/share (pre-split).

2020 Peak: ~$20/share (pre-split).

Jan 2025: AMRN executes a 20:1 reverse split just to avoid delisting.

May 2025: Trading at ~$10/share post-split = $0.50 pre-split.

🔻 97.5% collapse from peak.
🔻 50% loss over 18 years, despite FDA approval and a landmark CV outcomes trial.

This wasn’t a failure of the science — this was a failure of leadership.

Time for Consequences — Including Legal Ones

The CEO at the time of REDUCE-IT, John Thero, and the Board of Directors that enabled and approved this failed strategy, should be investigated for fiduciary malfeasance.

Under corporate law, executives and directors have a legal obligation to act in the best interests of shareholders. This includes:

Making commercially sound decisions.

Avoiding gross negligence in trial planning and IP strategy.

Taking reasonable steps to protect and grow shareholder value.

Failing to include statin-intolerant patients — when doing so was obvious, feasible, and potentially game-changing — meets the threshold of gross negligence, if not willful disregard of fiduciary duty.

Shareholder Action is Not Just Justified — It’s Overdue:

Shareholders should pursue legal counsel to explore:

Civil action for fiduciary breach against former executives.

Clawbacks of performance bonuses and golden parachutes.

Board accountability through proxy action and removal campaigns.

The leadership that presided over this disaster should not be allowed to walk away unscathed — they should face real consequences.

Final Judgment:

This isn’t biotech risk. This is executive failure — clear, preventable, and devastating.
Shareholders have been left holding worthless paper because of decisions no prudent leader would have made. The people responsible should face legal and financial consequences.

Ralpheys Take :

For those of you still holding onto this failure this would appear to be your only chance of getting some of your lost millions back as its not going to happen with the stock